drugset / Trial / NCT00210652

An Open-Label Extension Study to Evaluate the Safety and Effectiveness of RWJ 333369 in Patients With Epilepsy

NCT00210652

Phase 2 Completed 47 enrolled SK Life Science, Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and preliminary effectiveness of the novel compound RWJ-333369 in patients with partial onset seizures who are currently being treated with 1 or 2 concomitant antiepileptic drugs.

Timeline

Start
2004-07
Primary completion
2010-03
Completion
2010-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Carisbamate Small molecule 250 mg
Subject Carisbamate Small molecule 1200 mg

Indications